Best Researcher Award
Rut Meseguer Naturil
Health Research Institute INCLIVA, Spain
Rut Meseguer Naturil is a researcher affiliated with the Health Research Institute INCLIVA in Spain whose documented research output includes work in immunology and translational biomedical science. The available publication record highlights research involving natural killer (NK) cell biology, immunotherapy manufacturing, and therapeutic strategies for severe infectious disease. These contributions provide a basis for consideration within the Best Researcher Award category of the International Academic Excellence Awards.
Abstract
The research record associated with Rut Meseguer Naturil encompasses biomedical investigation relevant to immune-cell biology and translational medicine. A recent publication examines how donor NKG2A/NKG2C immunophenotypes influence the GMP-compliant manufacturing potential of NK cells for adoptive immunotherapy, connecting donor characteristics with the practical development of cellular therapeutic products [1]. Earlier work addressed combined therapeutic approaches in severe-to-critical COVID-19, contributing to the broader understanding of treatment strategies for complex infectious disease [2].
Keywords
NK cells, natural killer cells, NKG2A, NKG2C, adoptive immunotherapy, GMP manufacturing, immunology, COVID-19, translational medicine, biochemistry, molecular biology.
Introduction
Natural killer cells are an important component of the human immune system and have attracted substantial interest as candidates for cellular immunotherapy. Their therapeutic development requires reproducible manufacturing processes and careful consideration of biological variability. Research examining donor immunophenotypes can therefore help clarify factors associated with NK-cell production and downstream therapeutic applications [1].
Research Profile
The documented research profile is situated within Biochemistry, Genetics and Molecular Biology and intersects with immunology and translational biomedical research. The available record identifies two documents, while citation and h-index information has not been supplied. The publications demonstrate engagement with clinically relevant questions involving immune-cell therapies and severe infectious disease.
Research Contributions
- Investigated donor NKG2A/NKG2C immunophenotypes in relation to GMP-compliant NK-cell manufacturing for adoptive immunotherapy [1].
- Contributed to research evaluating rationales for combined therapies in severe-to-critical COVID-19 patients [2].
- Connected laboratory immunology with translational considerations relevant to cellular therapy and clinical treatment strategies.
Publications
Donor NKG2A/NKG2C Immunophenotype Influences the GMP-Compliant Manufacturing Potential of NK Cells for Adoptive Immunotherapy. Cancers, August 2026.[1].
Rationale for combined therapies in severe-to-critical COVID-19 patients. Frontiers in Immunology, September 11, 2023. [2].
Research Impact
The research addresses practical and clinically relevant questions in contemporary biomedical science. Work on GMP-compliant NK-cell manufacturing is particularly relevant to the translation of immune-cell research into standardized therapeutic products, while the COVID-19 publication contributes to the evidence base surrounding combination treatment strategies [1] [2].
Award Suitability
Rut Meseguer Naturil’s documented publications provide evidence of research activity spanning immune-cell biology, cellular therapy manufacturing, and clinical immunology. The combination of methodological and translational themes is relevant to the Best Researcher Award, particularly within the stated Biochemistry, Genetics and Molecular Biology subject area. Award assessment should consider the complete research record, including independently verifiable publications, scholarly impact, innovation, and broader contributions.
Conclusion
The available record presents Rut Meseguer Naturil as a researcher contributing to biomedical topics with relevance to immunotherapy and infectious disease. The documented studies provide a scholarly basis for recognition in the Best Researcher Award category, while further evaluation of the complete publication and impact record would provide a more comprehensive assessment.
External Links
References
- Meseguer Naturil, R., et al. (2026). Donor NKG2A/NKG2C Immunophenotype Influences the GMP-Compliant Manufacturing Potential of NK Cells for Adoptive Immunotherapy. Cancers, 18(17), 2732.
https://doi.org/10.3390/cancers18172732
- Frontiers in Immunology. (2023). Rationale for combined therapies in severe-to-critical COVID-19 patients. Frontiers in Immunology. PMID: 37767093; PMCID: PMC10520558.
https://doi.org/10.3389/fimmu.2023.1232472
- MDPI. (2026). Cancers, Volume 18, Issue 17, Article 2732. Multidisciplinary Digital Publishing Institute.
https://www.mdpi.com/2072-6694/18/17/2732
- Europe PMC. (2023). Rationale for combined therapies in severe-to-critical COVID-19 patients. Europe PMC record, PMCID: PMC10520558.
https://europepmc.org/article/pmc/PMC10520558
- ORCID. (n.d.). Rut Meseguer Naturil — ORCID record. ORCID iD: 0000-0003-4376-5997.
https://orcid.org/0000-0003-4376-5997
- International Academic Excellence Awards. (n.d.). Academic Excellence Awards. Award program website.
https://academicexcellenceawards.com/